A comparison of the effects of insulin Detemir with insulin Glargine on weight gain in female adolescents and young adults with Type 1 Diabetes on a basal bolus regime

Trial Profile

A comparison of the effects of insulin Detemir with insulin Glargine on weight gain in female adolescents and young adults with Type 1 Diabetes on a basal bolus regime

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Insulin detemir (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 28 Jan 2016 Accrual to date is 86% according to United Kingdom Clinical Research Network record.
    • 28 Jan 2016 According to United Kingdom Clinical Research Network record, Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2015 Accrual to date is 85% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top